PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-4.34%
G&A reduction while Biotechnology median is 1.78%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-6.85%
Operating expenses reduction while Biotechnology median is 5.07%. Seth Klarman would investigate advantages.
-6.85%
Total costs reduction while Biotechnology median is 3.28%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
4.17%
D&A growth exceeding 1.5x Biotechnology median of 1.43%. Jim Chanos would check for overinvestment.
16.91%
EBITDA growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Operating income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.45%
Other expenses reduction while Biotechnology median is 0.20%. Seth Klarman would investigate advantages.
16.61%
Pre-tax income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
16.61%
Net income growth while Biotechnology declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
17.14%
EPS change of 17.14% versus flat Biotechnology. Walter Schloss would verify quality.
17.14%
Diluted EPS change of 17.14% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.